NCT07275437

Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function Assessments

A Randomized, Controlled Trial Investigating the Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With a Reduced Ejection Fraction With Limited Standardized Kidney Function Assessments (RESUME-HF-Kidney)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 344 (estimated)
• Sponsor: University Medical Center Groningen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) constitutes of four medications that substantially reduce morbidity and mortality, and improve quality of life. In routine clinical practice, various physician- and patient-related factors lead to suboptimal initiation and uptitration of GDMT to optimal dosing, which is associated with worse patient outcomes. A perceived major barrier to the optimalization of GDMT are changes in kidney function and electrolytes, which prompts physicians to halt uptitration, reduce doses, or even discontinue GDMT. Changes in kidney function and electrolytes during optimalization of GDMT are common, but not associated with adverse events. The hypothesis of this study is that a reduction in the number of kidney function assessments during initiation and uptitration of GDMT in HFrEF patients will lead to higher achieved doses of GDMT without safety concerns.

Detailed description

Objective: To assess the effect of a reduction in kidney function assessments during optimalization of GDMT in patients with HFrEF on the achieved GDMT doses, safety, and clinical outcomes. Study design: Randomized, controlled open-label study Study population: 344 patients with new-onset or sub-optimally treated HFrEF referred to the outpatient clinic for optimalization of GDMT Intervention (if applicable): Randomization to limited number of kidney function assessments or standard of care Primary endpoint: The achieved average percentage dose of reno-active GDMT at 6 months relative to optimal dose. Secondary endpoints: The achieved percentage dose of the individual reno-active GDMT drug classes at 6 months relative to optimal dose, and time to first occurrence of unplanned heart failure visit, heart failure hospitalization, or all-cause mortality till 9 months. Safety endpoints: Incidence of doubling of creatinine, estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73 m2, potassium \>6 mmol/L, or potassium \<3.5 mmol/L at any timepoint. An additional composite kidney endpoint is defined as a combination of hospitalization for kidney failure, dialysis or end-stage kidney disease (eGFR \<15 mL/min/1.73 m2).

Conditions

• Heart Failure
• Heart Failure and Reduced Ejection Fraction
• Heart Failure and Mildly Reduced Ejection Fraction

Interventions

Type	Name	Description
OTHER	Blinded kidney function assessments	Kidney function results will be blinded in the intervention group, except at baseline, three months, and six months.

Timeline

• Start date: 2026-04-01
• Primary completion: 2030-01-01
• Completion: 2030-01-01
• First posted: 2025-12-10
• Last updated: 2025-12-18

Locations

2 sites across 1 country: Netherlands